Gene Logic has appointed Thomas Barnes as senior vice president of discovery. In this position, Barnes will lead the company's drug-repositioning discovery efforts.
Barnes was a co-founder of the drug-repositioning initiative within Millennium Pharmaceuticals, which Gene Logic acquired in 2004.
Prior to joining Gene Logic, Barnes led Millennium's development and application of genomic technologies for downstream drug development. He has also held academic appointments at Harvard Medical School and McGill University.
He will take over the duties of Louis Tartaglia, senior vice president of drug repositioning at Gene Logic, who will resign on June 15 to become a partner in a venture capital firm. Tartaglia, who also co-founded the drug-repositioning service at Millennium, will continue to serve on a consulting basis as a senior advisor.
Gene Logic has also added David Urdal and Mark Gabrielson to its board of directors, while Jules Blake has retired from the board.
Urdal is currently senior vice president and CSO at Dendreon. Previously he was president of Immunex.
Gabrielson is co-founder, director, and CEO of Pulmatrix, and has held posts at SmithKline Beecham and Prince Ventures.
Blake has been a board director at Gene Logic since 1994.
Thermo Fisher Scientific said last week that Paul Meister will retire from his position on the company’s board in mid-May. Meister has decided not to run for re-election at the annual stockholder’s meeting, and has relinquished his duties as chairman.
The J. Craig Venter Institute is shuffling some of its executive staff while it restructures its two research divisions — the Institute for Genomic Research and the Center for the Advancement of Genomics — into several more tightly focused units.
The institute said that Craig Venter will remain JCVI chairman and president; Robert Strausberg will move from his job as president of the TCAG division to become deputy director of the JCVI; and Marv Frazier will shift from vice president of research at TCAG to become executive vice president of research of JCVI.
The Foundation for the National Institutes of Health has hired C. Anthony Altar to be director of its Biomarkers Consortium, a large-scale, public-private biomedical research partnership formed to identify and qualify new biomarkers for use by biomedical researchers, regulators, and health care providers.
Altar has been chief scientific officer of Psychiatric Genomics, director of global neuroscience research at Otsuka America Pharmaceuticals, and a senior staff scientist, neurobiology at Regeneron Pharmaceuticals.
He received his PhD in psychology from the University of California, Santa Barbara, and holds a BS in psychobiology from the University of California, Los Angeles.